Abstract: Provided herein are low impurity compositions comprising a compound represented which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFR? kinases, and oncogenic forms thereof.
Type:
Grant
Filed:
August 6, 2024
Date of Patent:
February 4, 2025
Assignee:
Deciphera Pharmaceuticals, LLC
Inventors:
Michael D. Kaufman, Scott Bone, Corey Bloom, Fred Jordan
Abstract: Provided herein are low impurity compositions comprising a compound represented by Formula (I): which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFR? kinases, and oncogenic forms thereof.
Type:
Grant
Filed:
August 6, 2024
Date of Patent:
February 4, 2025
Assignee:
Deciphera Pharmaceuticals, LLC
Inventors:
Michael D. Kaufman, Scott Bone, Corey Bloom, Fred Jordan
Abstract: The present disclosure relates to the use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea or 1-(5-(7-amino-1-ethyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-4-bromo-2-fluorophenyl)-3-phenylurea, or a pharmaceutically acceptable salt thereof, in combination with a MAPKAP pathway inhibitor such as for example a RAS, RAF, MEK, or ERK inhibitor for the treatment of mastocytosis.
Type:
Grant
Filed:
July 30, 2020
Date of Patent:
October 1, 2024
Assignee:
Deciphera Pharmaceuticals, LLC
Inventors:
Daniel L. Flynn, Bryan D. Smith, Anu Gupta
Abstract: Provided herein are low impurity compositions comprising a compound represented by Formula (I): which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFR? kinases, and oncogenic forms thereof.
Type:
Grant
Filed:
November 22, 2023
Date of Patent:
August 20, 2024
Assignee:
Deciphera Pharmaceuticals, LLC
Inventors:
Michael D. Kaufman, Scott Bone, Corey Bloom, Fred Jordan
Abstract: The present disclosure relates to methods of treating gastrointestinal stromal tumors to a subject in need thereof, comprising administering to the subject a therapeutically effective amount of ripretinib or a pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
November 2, 2023
Date of Patent:
August 13, 2024
Assignee:
Deciphera Pharmaceuticals, LLC
Inventors:
Rodrigo Ruiz Soto, Oliver Rosen, Jama Pitman
Abstract: The present disclosure relates to methods of treating gastrointestinal stromal tumors to a subject in need thereof, comprising administering to the subject a therapeutically effective amount of ripretinib or a pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
November 2, 2023
Date of Patent:
August 13, 2024
Assignee:
Deciphera Pharmaceuticals, LLC
Inventors:
Rodrigo Ruiz Soto, Oliver Rosen, Jama Pitman
Abstract: The present disclosure relates to methods of treating gastrointestinal stromal tumors to a subject in need thereof, comprising administering to the subject a therapeutically effective amount of ripretinib or a pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
November 2, 2023
Date of Patent:
July 2, 2024
Assignee:
Deciphera Pharmaceuticals, LLC
Inventors:
Rodrigo Ruiz Soto, Oliver Rosen, Jama Pitman
Abstract: The present disclosure relates to methods of treating gastrointestinal stromal tumors to a subject in need thereof, comprising administering to the subject a therapeutically effective amount of ripretinib or a pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
November 2, 2023
Date of Patent:
July 2, 2024
Assignee:
Deciphera Pharmaceuticals, LLC
Inventors:
Rodrigo Ruiz Soto, Oliver Rosen, Jama Pitman
Abstract: Provided herein are low impurity compositions comprising a compound represented by Formula (I): which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFR? kinases, and oncogenic forms thereof.
Type:
Grant
Filed:
November 22, 2023
Date of Patent:
July 2, 2024
Assignee:
Deciphera Pharmaceuticals, LLC
Inventors:
Michael D. Kaufman, Scott Bone, Corey Bloom, Fred Jordan
Abstract: The present disclosure relates to methods of treating gastrointestinal stromal tumors to a subject in need thereof, comprising administering to the subject a therapeutically effective amount of ripretinib or a pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
November 2, 2023
Date of Patent:
July 2, 2024
Assignee:
Deciphera Pharmaceuticals, LLC
Inventors:
Rodrigo Ruiz Soto, Oliver Rosen, Jama Pitman
Abstract: The present disclosure relates to the use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea or 1-(5-(7-amino-1-ethyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-4-bromo-2-fluorophenyl)-3-phenylurea, or a pharmaceutically acceptable salt thereof, in combination with a MAPKAP kinase inhibitor for the treatment of cancers, including c-KIT-mediated cancers, such as GIST.
Type:
Grant
Filed:
July 30, 2020
Date of Patent:
May 21, 2024
Assignee:
Deciphera Pharmaceuticals, LLC
Inventors:
Daniel L. Flynn, Bryan D. Smith, Anu Gupta
Abstract: Provided herein are low impurity compositions comprising a compound represented by Formula (I): which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFR? kinases, and oncogenic forms thereof.
Type:
Grant
Filed:
November 22, 2023
Date of Patent:
April 30, 2024
Assignee:
Deciphera Pharmaceuticals, LLC
Inventors:
Michael D. Kaufman, Scott Bone, Corey Bloom, Fred Jordan
Abstract: The present disclosure relates to methods of treating gastrointestinal stromal tumors to a subject in need thereof, comprising administering to the subject a therapeutically effective amount of ripretinib or a pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
July 20, 2022
Date of Patent:
April 30, 2024
Assignee:
Deciphera Pharmaceuticals, LLC
Inventors:
Rodrigo Ruiz Soto, Oliver Rosen, Jama Pitman
Abstract: Provided herein are low impurity compositions comprising a compound represented by Formula (I): which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFR? kinases, and oncogenic forms thereof.
Type:
Grant
Filed:
October 19, 2023
Date of Patent:
March 5, 2024
Assignee:
Deciphera Pharmaceuticals, LLC
Inventors:
Michael D. Kaufman, Scott Bone, Corey Bloom, Fred Jordan
Abstract: Provided herein are low impurity compositions comprising a compound represented by Formula (I): which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFR? kinases, and oncogenic forms thereof.
Type:
Grant
Filed:
October 19, 2023
Date of Patent:
February 27, 2024
Assignee:
Deciphera Pharmaceuticals, LLC
Inventors:
Michael D. Kaufman, Scott Bone, Corey Bloom, Fred Jordan
Abstract: Described herein are compounds, such as compounds represented by Formula I-R: and pharmaceutically acceptable salts, enantiomers, stereoisomers, and tautomers thereof, that are inhibitors of GCN2 kinase or PERK kinase, and methods of treating diseases, including diseases associated with GCN2 kinase or PERK kinase, with said compounds.
Type:
Grant
Filed:
November 17, 2021
Date of Patent:
February 27, 2024
Assignee:
Deciphera Pharmaceuticals, LLC
Inventors:
Daniel L. Flynn, Patrick Kearney, Jeffery Zwicker, Gada Al-Ani, Salim Javed, Yu Mi Ahn, Kristen Stoltz, Bertrand Le Bourdonnec
Abstract: Provided herein are low impurity compositions comprising a compound represented by Formula (I): which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFR? kinases, and oncogenic forms thereof.
Type:
Grant
Filed:
August 11, 2023
Date of Patent:
February 20, 2024
Assignee:
Deciphera Pharmaceuticals, LLC
Inventors:
Michael D. Kaufman, Scott Bone, Corey Bloom, Fred Jordan
Abstract: Provided herein are low impurity compositions comprising a compound represented by Formula (I): which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFR? kinases, and oncogenic forms thereof.
Type:
Grant
Filed:
December 30, 2022
Date of Patent:
February 13, 2024
Assignee:
Deciphera Pharmaceuticals, LLC
Inventors:
Michael D. Kaufman, Scott Bone, Corey Bloom, Fred Jordan
Abstract: Described herein are methods of treating cancers and other tumors related to the decreased proliferation, the depletion, or the repolarization of tumor-associated macrophages (TAMs) and treatment of associated disorders, including tenosynovial giant cell tumor (TGCT) and diffuse-type tenosynovial giant cell tumor (DTGCT).
Type:
Application
Filed:
April 28, 2023
Publication date:
December 28, 2023
Applicant:
Deciphera Pharmaceuticals, LLC
Inventors:
Daniel L. Flynn, Bryan D. Smith, Rodrigo Ruiz Soto, Keisuke Kuida